Revolutionising cellular therapies for cancer and beyond

We’re developing more precise and more accessible treatment options for patients with solid cancers, endometriosis and Alzheimer’s disease

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers, endometriosis and Alzheimer’s disease. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer and beyond.

Learn more about us

Some of our partners

Latest news

The critical importance of navigating the complexity of healthcare markets

By Christine Filippis / July 11, 2025
In the competitive biotech landscape, groundbreaking science alone isn't enough. As highlighted in a recent article by Dynamic Business, Cartherics'...
Read More

Cartherics COO Dr Ian Nisbet on the promise of CAR-NK cells for cancer and endometriosis at BIO 2025

By Christine Filippis / June 18, 2025
In the lead-up to BIO, Cartherics’ COO, Dr Ian Nisbet was interviewed by BioSpectrum Asia to discuss the company’s innovative...
Read More

Using Gene-edited Killer Cells to Target Cancer, Endometriosis and Beyond

By Christine Filippis / June 12, 2025
Cartherics is delighted to be featured in the June 2025 issue of Pharma Technology Focus, drawing attention to our innovative...
Read More
1 2 3 66